Want to see AU:ZLD full AI Analyst Report?
Top Page
Zelira Therapeutics
(Sydney:ZLD)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.51
▲(1.00% Upside)
Action:Reiterated
Date:01/21/26
Zelira Therapeutics' score of 52 reflects significant financial weaknesses, including revenue decline, negative equity, and cash burn, which heavily weigh down the outlook. Positive technical momentum provides some upside, but speculative valuation limits confidence. Caution is advised.
Positive Factors
Lean cost base (small headcount)
A very small employee base implies a lean operating structure that can reduce fixed overhead and slow cash burn. Over 2-6 months this provides flexibility to allocate capital to priority projects or scale via outsourcing and partnerships rather than costly internal expansion.
Negative Factors
Severe revenue decline and unprofitable operations
An extreme revenue collapse and persistent negative margins indicate the core business is not currently monetizing at scale. Over the medium term this erodes operating leverage, undermines reinvestment capacity, and requires meaningful new revenue engines or partner deals to restore sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Lean cost base (small headcount)
A very small employee base implies a lean operating structure that can reduce fixed overhead and slow cash burn. Over 2-6 months this provides flexibility to allocate capital to priority projects or scale via outsourcing and partnerships rather than costly internal expansion.
Read all positive factors
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.95M
Dividend YieldN/A
Average Volume (3M)1.92K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding13,147,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zelira Therapeutics Business Overview & Revenue Model
Company Description
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ b...
How the Company Makes Money
Zelira’s monetization has historically been intended to come from a mix of (1) commercialization of proprietary cannabinoid-based products (including consumer health/wellness products) through sales via distribution and retail/online channels, and...
Zelira Therapeutics Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 656.00 | 94.95K | 301.12K | 1.54M | 663.32K |
| Gross Profit | -802.95K | 10.28K | -3.22M | -5.72M | -39.16K |
| EBITDA | -4.17M | -36.44M | -6.79M | -13.06M | -9.41M |
| Net Income | -3.63M | -36.57M | -5.57M | -11.95M | -8.55M |
Balance Sheet | |||||
| Total Assets | 1.30M | 5.18M | 33.89M | 37.70M | 39.37M |
| Cash, Cash Equivalents and Short-Term Investments | 5.66K | 586.16K | 146.21K | 2.75M | 4.97M |
| Total Debt | 2.14M | 5.95M | 437.90K | 500.91K | 551.08K |
| Total Liabilities | 5.59M | 9.36M | 2.18M | 2.01M | 1.54M |
| Stockholders Equity | -4.46M | -4.51M | 31.80M | 35.20M | 37.83M |
Cash Flow | |||||
| Free Cash Flow | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Operating Cash Flow | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Investing Cash Flow | 1.15M | 919.74K | 2.83M | -207.78K | 1.38M |
| Financing Cash Flow | 3.19M | 3.92M | 1.77M | 7.10M | 10.53M |
Zelira Therapeutics Technical Analysis
Neutral
0.50
Price Trends
0.50
Positive
0.50
Positive
0.49
Positive
Market Momentum
>-0.01
Negative
38.51
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZLD, the sentiment is Neutral. The current price of 0.5 is below the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.50, and above the 200-day MA of 0.49, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.51 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ZLD.
Zelira Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$136.20M | -15.96 | -100.58% | ― | ― | -9.57% | |
48 Neutral | AU$54.73M | -0.43 | -131.13% | ― | 2086.71% | -116.20% | |
45 Neutral | AU$61.22M | -16.96 | -68.12% | ― | ― | 57.89% | |
44 Neutral | AU$167.78M | -7.93 | -134.14% | ― | ― | -70.59% | |
43 Neutral | AU$104.86M | -1.96 | -265.55% | ― | -26.58% | -100.90% |
* Healthcare Sector Average
AU:ZLD
Zelira Therapeutics
0.50
0.09
20.48%
AU:ACW
Actinogen Medical
0.05
0.02
64.29%
AU:ENP
Tryptamine Therapeutics
0.04
<0.01
25.81%
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.12
-40.68%
AU:ILA
Island Pharmaceuticals Ltd
0.49
0.28
133.33%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.14
-87.10%
Zelira Therapeutics Corporate Events
Zelira Secures US$33m for HOPE® 1 SPV to Advance FDA Autism Trial
Jul 30, 2026
Zelira Therapeutics has secured definitive agreements for a US$32.98 million capital raise into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$65.96 million and Zelira’s post-money stake at roughly US$26.19 million. On...
ASX Sets Deadlines for Long-Term Suspended Companies Facing Delisting Risk
Jul 10, 2026
The ASX has issued a market announcement listing entities whose securities have been suspended from trading for more than three months, detailing for each the outstanding periodic financial and activity reports and the deadlines by which these doc...
Zelira Director Converts Convertible Notes, Boosting Equity Stake
Jul 2, 2026
Zelira Therapeutics has disclosed a change in director Osagie Imasogie’s interests following the conversion of a portion of his convertible notes into ordinary shares. Imasogie acquired 1,250,000 shares at US$0.40 per share through note conv...
Zelira Therapeutics Ceases 2.25 Million Convertible Notes
Jul 2, 2026
Zelira Therapeutics has notified the market of the cessation of 2,250,000 ZLDAM convertible notes, effective 29 June 2026, under an Appendix 3H filing. The removal of these convertible notes alters the company’s issued capital profile and ma...
Zelira Therapeutics Seeks ASX Quotation for 1.25 Million New Shares
Jul 1, 2026
Zelira Therapeutics has applied for quotation on the ASX of 1,250,000 new fully paid ordinary shares, which were issued on July 1, 2026. The additional securities expand the company’s quoted share capital, potentially improving liquidity in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.